InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,171.20
(
1.12%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.21
(
-1.24%
)
Bitcoin
61,990.20
(
2.87%
)
Post# of 252342
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119913
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 131989

Tuesday, 11/29/2011 1:51:44 PM

Tuesday, November 29, 2011 1:51:44 PM

Post# of 252342
Re: Eliquis priority review

Ordinarily, I wouldn’t ascribe much significance to an FDA decision to grant priority review, but this could be an exception. Why? Because the FDA gave the Xarelto NDA in the exact same indication a standard review (#msg-64878521). At the very least, the FDA’s granting a priority review for Eliquis means that the FDA reviewers think Eliquis has something to offer in this indication beyond what Pradaxa and Xarelto can. The data for Eliquis in warfarin-intolerant patients provides such a justification, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up